...
search icon
fate-img

Fate Therapeutics Inc Share Price

FATE
NMQ
$1.37
+$0.03
(2.24%)
1D
Industry: Biotechnology Sector: Health Care

Fate Therapeutics Inc Analyst Forecast

Fate Therapeutics Inc Share Price Chart

Fate Therapeutics Inc Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$154.57M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.34M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.25
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.66 L
$1.94 H
$1.37

About Fate Therapeutics Inc, Common Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California. more

Industry: BiotechnologySector: Health Care

Fate Therapeutics Inc Stock Returns

Time FrameFATESectorS&P500
1-Week Return16.24%0.72%-1.31%
1-Month Return23.64%1.27%0.78%
3-Month Return33.33%3.13%3.46%
6-Month Return13.33%15.81%6.19%
1-Year Return-11.11%8.89%11.68%
3-Year Return-77.45%20.79%71.21%
5-Year Return-98.67%35.89%74.81%
10-Year Return-12.82%138.44%256.59%

Fate Therapeutics Inc Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue31.43M55.85M96.30M63.53M13.63M[{"date":"2020-12-31","value":32.64,"profit":true},{"date":"2021-12-31","value":57.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":65.97,"profit":true},{"date":"2024-12-31","value":14.15,"profit":true}]
Cost of Revenue125.62M5.85M13.76M157.19M18.96M[{"date":"2020-12-31","value":79.92,"profit":true},{"date":"2021-12-31","value":3.72,"profit":true},{"date":"2022-12-31","value":8.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":12.06,"profit":true}]
Gross Profit(94.19M)50.00M96.30M(93.65M)13.63M[{"date":"2020-12-31","value":-97.81,"profit":false},{"date":"2021-12-31","value":51.92,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-97.25,"profit":false},{"date":"2024-12-31","value":14.15,"profit":true}]
Gross Margin(299.64%)89.52%100.00%(147.41%)100.00%[{"date":"2020-12-31","value":-299.64,"profit":false},{"date":"2021-12-31","value":89.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-147.41,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses33.90M266.99M404.69M96.86M223.91M[{"date":"2020-12-31","value":8.38,"profit":true},{"date":"2021-12-31","value":65.97,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":23.93,"profit":true},{"date":"2024-12-31","value":55.33,"profit":true}]
Operating Income(128.09M)(216.99M)(308.39M)(190.51M)(210.28M)[{"date":"2020-12-31","value":-12808500000,"profit":false},{"date":"2021-12-31","value":-21699400000,"profit":false},{"date":"2022-12-31","value":-30838600000,"profit":false},{"date":"2023-12-31","value":-19051100000,"profit":false},{"date":"2024-12-31","value":-21027600000,"profit":false}]
Total Non-Operating Income/Expense(42.90M)6.15M32.51M45.23M41.30M[{"date":"2020-12-31","value":-94.84,"profit":false},{"date":"2021-12-31","value":13.6,"profit":true},{"date":"2022-12-31","value":71.86,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":91.31,"profit":true}]
Pre-Tax Income(173.39M)(212.15M)(281.72M)(160.93M)(186.26M)[{"date":"2020-12-31","value":-17338700000,"profit":false},{"date":"2021-12-31","value":-21215100000,"profit":false},{"date":"2022-12-31","value":-28172100000,"profit":false},{"date":"2023-12-31","value":-16092800000,"profit":false},{"date":"2024-12-31","value":-18626200000,"profit":false}]
Income Taxes(3.09M)(5.85M)(26.66M)18.11M-[{"date":"2020-12-31","value":-17.04,"profit":false},{"date":"2021-12-31","value":-32.3,"profit":false},{"date":"2022-12-31","value":-147.21,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(170.30M)(206.30M)(255.06M)(179.04M)-[{"date":"2020-12-31","value":-17030000000,"profit":false},{"date":"2021-12-31","value":-20630100000,"profit":false},{"date":"2022-12-31","value":-25505600000,"profit":false},{"date":"2023-12-31","value":-17904210500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(173.39M)(212.15M)(281.72M)(173.17M)(186.26M)[{"date":"2020-12-31","value":-17338700000,"profit":false},{"date":"2021-12-31","value":-21215100000,"profit":false},{"date":"2022-12-31","value":-28172100000,"profit":false},{"date":"2023-12-31","value":-17316900000,"profit":false},{"date":"2024-12-31","value":-18626200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(173.39M)(212.15M)(255.06M)(160.93M)(186.26M)[{"date":"2020-12-31","value":-17338700000,"profit":false},{"date":"2021-12-31","value":-21215100000,"profit":false},{"date":"2022-12-31","value":-25505600000,"profit":false},{"date":"2023-12-31","value":-16092800000,"profit":false},{"date":"2024-12-31","value":-18626200000,"profit":false}]
EPS (Diluted)(2.08)(2.23)(2.91)(1.64)(1.64)[{"date":"2020-12-31","value":-208,"profit":false},{"date":"2021-12-31","value":-223,"profit":false},{"date":"2022-12-31","value":-291,"profit":false},{"date":"2023-12-31","value":-164,"profit":false},{"date":"2024-12-31","value":-164,"profit":false}]

Fate Therapeutics Inc Ratios

Fate Therapeutics Inc Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

FATE
Cash Ratio 7.66
Current Ratio 7.87

Fate Therapeutics Inc Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

FATE
ROA (LTM) -23.85%
ROE (LTM) -52.35%

Fate Therapeutics Inc Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

FATE
Debt Ratio Lower is generally better. Negative is bad. 0.32
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.68

Fate Therapeutics Inc Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

FATE
Trailing PE NM
Forward PE NM
P/S (TTM) 20.20
P/B 0.62
Price/FCF NM
EV/R 1.12
EV/Ebitda NM
PEG NM

FAQs

What is Fate Therapeutics Inc share price today?

Fate Therapeutics Inc (FATE) share price today is $1.37

Can Indians buy Fate Therapeutics Inc shares?

Yes, Indians can buy shares of Fate Therapeutics Inc (FATE) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FATE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Fate Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Fate Therapeutics Inc (FATE) via the Vested app. You can start investing in Fate Therapeutics Inc (FATE) with a minimum investment of $1.

How to invest in Fate Therapeutics Inc shares from India?

You can invest in shares of Fate Therapeutics Inc (FATE) via Vested in three simple steps:

  • Click on Sign Up or Invest in FATE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Fate Therapeutics Inc shares
What is Fate Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Fate Therapeutics Inc (FATE) is $1.94. The 52-week low price of Fate Therapeutics Inc (FATE) is $0.66.

What is Fate Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Fate Therapeutics Inc (FATE) is

What is Fate Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Fate Therapeutics Inc (FATE) is 0.62

What is Fate Therapeutics Inc dividend yield?

The dividend yield of Fate Therapeutics Inc (FATE) is 0.00%

What is the Market Cap of Fate Therapeutics Inc?

The market capitalization of Fate Therapeutics Inc (FATE) is $154.57M

What is Fate Therapeutics Inc's stock symbol?

The stock symbol (or ticker) of Fate Therapeutics Inc is FATE

How Can Investors Use Fate Therapeutics Inc Share Price Data for Long-Term Investment Decisions?

Consider the share price of Fate Therapeutics Inc as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Fate Therapeutics Inc has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Fate Therapeutics Inc shares for Indian investors?

When investing in Fate Therapeutics Inc shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Fate Therapeutics Inc stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Fate Therapeutics Inc share price with other stocks in the same sector?

Rather than merely checking the share price of Fate Therapeutics Inc and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Fate Therapeutics Inc stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top